{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-031624","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2023-07-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.242049+00:00","generated_at":"2026-06-13T12:47:26.151123+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nkarta appoints Alyssa Levin as CFO and Business Officer effective July 1","bullets":["Annual base salary of $450k, sign-on bonus of $20k, and a stock option for 442,400 shares.","Option vests 25% on July 1, 2024, then monthly over 36 months; exercise price = June 30 closing.","Levin previously CFO at ViaCyte (acquired by Vertex), Tentarix, and Bird Rock Bio.","Target annual incentive bonus set at 40% of base salary.","Company is developing engineered NK cell therapies for cancer (NKX101, NKX019)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-031624","json":"https://secwatch.observer/filing/0000950170-23-031624.json","markdown":"https://secwatch.observer/filing/0000950170-23-031624.md","text":"https://secwatch.observer/filing/0000950170-23-031624.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023031624/0000950170-23-031624-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023031624/nktx-20230629.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T12:47:26.151123+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fdf322c658","claim":"Alyssa Levin was appointed as Chief Financial and Business Officer at Nkarta, Inc..","evidence_excerpt":"On June 29, 2023, Nkarta, Inc.'s (the “Company”) Board of Directors (the “Board”) appointed Alyssa Levin as the Company’s Chief Financial and Business Officer and the principal financial and accounting officer, effective July 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023031624/0000950170-23-031624-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial and Business Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}